104 related articles for article (PubMed ID: 4064938)
1. [Continuous subcutaneous deferoxamine treatment in thalassemia major. Decrease of hemosiderosis and improvement of liver function].
Krüger N; Ullrich D; Tillmann W; Schröter W
Dtsch Med Wochenschr; 1985 Nov; 110(48):1848-51. PubMed ID: 4064938
[TBL] [Abstract][Full Text] [Related]
2. [Continuous subcutaneous deferoxamine infusions in thalassemia major. Improvement in glucose tolerance].
Krüger N; Stubbe P; Tillmann W; Schröter W
Dtsch Med Wochenschr; 1986 May; 111(18):698-701. PubMed ID: 3486106
[TBL] [Abstract][Full Text] [Related]
3. [Continuous subcutaneous desferrioxamine infusions in patients with hemosiderosis (author's transl)].
Tillmann W; König R; Schröder K; Schröter W
Monatsschr Kinderheilkd; 1982 Mar; 130(3):171-2. PubMed ID: 7087975
[No Abstract] [Full Text] [Related]
4. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
Krüger N; Kijewski H; König R; Tillmann W; Schröter W
Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
[TBL] [Abstract][Full Text] [Related]
5. Intensification of chelating-therapy in patients with thalassemia major.
Laws HJ; Göbel U; Christaras A; Janssen G
Klin Padiatr; 2005; 217(3):120-5. PubMed ID: 15858702
[TBL] [Abstract][Full Text] [Related]
6. Iron chelating therapy in thalassemia: current problems.
Russo G
Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
[No Abstract] [Full Text] [Related]
7. [Longitudinal growth of patients with homozygote beta-thalassemia during continuous subcutaneous infusion of deferoxamine].
Krüger N; Stubbe P; Tillmann W; Schröter W
Dtsch Med Wochenschr; 1986 Jan; 111(5):176-81. PubMed ID: 3943469
[TBL] [Abstract][Full Text] [Related]
8. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
Flynn DM; Hoffbrand AV; Politis D
Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
[No Abstract] [Full Text] [Related]
10. The treatment of hemosiderosis in thalassaemia major with desferrioxamine-B.
Kirimlidis S; Philippidis P; Drossos C; Economidis J
Helv Paediatr Acta; 1966 Sep; 21(4):343-50. PubMed ID: 5997620
[No Abstract] [Full Text] [Related]
11. Long-term administration of desferrioxamine in thalassaemia major.
Seshadri R; Colebatch JH; Gordon P; Ekert H
Arch Dis Child; 1974 Aug; 49(8):621-6. PubMed ID: 4278421
[TBL] [Abstract][Full Text] [Related]
12. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major.
Koren G; Kochavi-Atiya Y; Bentur Y; Olivieri NF
Int J Hematol; 1991 Oct; 54(5):371-5. PubMed ID: 1756248
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
Trans Assoc Am Physicians; 1977; 90():335-41. PubMed ID: 611665
[No Abstract] [Full Text] [Related]
14. The treatment of Cooley's anemia.
Nathan DG
Haematologica; 1990; 75 Suppl 5():57-65. PubMed ID: 2086382
[No Abstract] [Full Text] [Related]
15. [Thalassemia major: chelating therapy with deferoxamine].
Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
[No Abstract] [Full Text] [Related]
16. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously].
Ferrara M; Galdo Capotorti M; Ponte G; Esposito L
Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400
[No Abstract] [Full Text] [Related]
17. [Cardiac dysfunction in children with thalassemia major].
Angelika L; Graf N; Hoffmann W
Klin Padiatr; 1988; 200(2):102-7. PubMed ID: 3386182
[TBL] [Abstract][Full Text] [Related]
18. [Beta-thalassemia in Germany. Results of cooperative beta-thalassemia study].
Cario H; Stahnke K; Kohne E
Klin Padiatr; 1999; 211(6):431-7. PubMed ID: 10592921
[TBL] [Abstract][Full Text] [Related]
19. [Iron overload in a beta thalassemia heterozygote of the intermediate type in a subject of Alsation origin. Results of iron chelation treatment].
North ML; Lang JM; Bergerat JP; Giron C; Oberling F; Mayer S
Nouv Rev Fr Hematol (1978); 1984; 26(5):317-21. PubMed ID: 6334273
[TBL] [Abstract][Full Text] [Related]
20. [Hepatic pathology in beta-thalassemia major].
Gangemi B; Fischer A; Di Gregorio F; Leonardi S; Pastore R; Musumeci S
Pediatr Med Chir; 1986; 8(1):77-83. PubMed ID: 3725617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
